CN115969721A - Blue algae cream with soothing and repairing effects and suitable for children and preparation method thereof - Google Patents
Blue algae cream with soothing and repairing effects and suitable for children and preparation method thereof Download PDFInfo
- Publication number
- CN115969721A CN115969721A CN202211011651.1A CN202211011651A CN115969721A CN 115969721 A CN115969721 A CN 115969721A CN 202211011651 A CN202211011651 A CN 202211011651A CN 115969721 A CN115969721 A CN 115969721A
- Authority
- CN
- China
- Prior art keywords
- stirring
- skin
- children
- cream
- test
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000195493 Cryptophyta Species 0.000 title claims abstract description 40
- 239000006071 cream Substances 0.000 title claims abstract description 37
- 230000000694 effects Effects 0.000 title claims abstract description 37
- 238000002360 preparation method Methods 0.000 title abstract description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 30
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 23
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 21
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 21
- 239000003974 emollient agent Substances 0.000 claims abstract description 20
- 239000002738 chelating agent Substances 0.000 claims abstract description 17
- 239000002562 thickening agent Substances 0.000 claims abstract description 17
- 239000003906 humectant Substances 0.000 claims abstract description 15
- 240000000073 Achillea millefolium Species 0.000 claims abstract description 12
- 235000007754 Achillea millefolium Nutrition 0.000 claims abstract description 12
- 125000003118 aryl group Chemical group 0.000 claims abstract description 12
- 235000007164 Oryza sativa Nutrition 0.000 claims abstract description 10
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 10
- 238000000855 fermentation Methods 0.000 claims abstract description 10
- 230000004151 fermentation Effects 0.000 claims abstract description 10
- 239000000706 filtrate Substances 0.000 claims abstract description 10
- 235000009566 rice Nutrition 0.000 claims abstract description 10
- 239000011782 vitamin Substances 0.000 claims abstract description 4
- 229930003231 vitamin Natural products 0.000 claims abstract description 4
- 235000013343 vitamin Nutrition 0.000 claims abstract description 4
- 229940088594 vitamin Drugs 0.000 claims abstract description 4
- 150000003722 vitamin derivatives Chemical class 0.000 claims abstract description 4
- 240000007594 Oryza sativa Species 0.000 claims abstract 3
- 238000003756 stirring Methods 0.000 claims description 45
- 239000000047 product Substances 0.000 claims description 27
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 25
- 238000004519 manufacturing process Methods 0.000 claims description 14
- 229930182478 glucoside Natural products 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- 230000002829 reductive effect Effects 0.000 claims description 13
- -1 polydimethylsiloxane Polymers 0.000 claims description 12
- 235000011187 glycerol Nutrition 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- 238000010438 heat treatment Methods 0.000 claims description 9
- 229930003779 Vitamin B12 Natural products 0.000 claims description 8
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims description 8
- 239000011715 vitamin B12 Substances 0.000 claims description 8
- 235000019163 vitamin B12 Nutrition 0.000 claims description 8
- 239000004475 Arginine Substances 0.000 claims description 6
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 6
- 230000001804 emulsifying effect Effects 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 5
- 229940015975 1,2-hexanediol Drugs 0.000 claims description 5
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 5
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 claims description 5
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical group [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 5
- 244000179970 Monarda didyma Species 0.000 claims description 5
- 235000010672 Monarda didyma Nutrition 0.000 claims description 5
- 229920002125 Sokalan® Polymers 0.000 claims description 5
- 229960001631 carbomer Drugs 0.000 claims description 5
- 238000004140 cleaning Methods 0.000 claims description 5
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 5
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 claims description 5
- 235000013399 edible fruits Nutrition 0.000 claims description 5
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 claims description 5
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 claims description 5
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 5
- 229920000058 polyacrylate Polymers 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 4
- 238000005070 sampling Methods 0.000 claims description 4
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 claims description 3
- 229930003270 Vitamin B Natural products 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 238000007599 discharging Methods 0.000 claims description 3
- 239000010419 fine particle Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 238000005086 pumping Methods 0.000 claims description 3
- 238000005507 spraying Methods 0.000 claims description 3
- 235000019156 vitamin B Nutrition 0.000 claims description 3
- 239000011720 vitamin B Substances 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- 239000004386 Erythritol Substances 0.000 claims description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 2
- 235000019414 erythritol Nutrition 0.000 claims description 2
- 229940009714 erythritol Drugs 0.000 claims description 2
- 239000004909 Moisturizer Substances 0.000 claims 1
- 230000001333 moisturizer Effects 0.000 claims 1
- 230000037307 sensitive skin Effects 0.000 abstract description 9
- 231100000344 non-irritating Toxicity 0.000 abstract description 7
- 239000003795 chemical substances by application Substances 0.000 abstract description 2
- 238000012360 testing method Methods 0.000 description 113
- 210000003491 skin Anatomy 0.000 description 84
- 241001465754 Metazoa Species 0.000 description 21
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 16
- 238000011156 evaluation Methods 0.000 description 13
- 206010015150 Erythema Diseases 0.000 description 10
- 230000001815 facial effect Effects 0.000 description 10
- 239000004310 lactic acid Substances 0.000 description 8
- 235000014655 lactic acid Nutrition 0.000 description 8
- 241000209094 Oryza Species 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 238000010998 test method Methods 0.000 description 7
- 102000001554 Hemoglobins Human genes 0.000 description 6
- 108010054147 Hemoglobins Proteins 0.000 description 6
- 239000000306 component Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 210000000434 stratum corneum Anatomy 0.000 description 6
- 230000000007 visual effect Effects 0.000 description 6
- 206010015946 Eye irritation Diseases 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 238000009395 breeding Methods 0.000 description 5
- 230000001488 breeding effect Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 231100000013 eye irritation Toxicity 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 241000192700 Cyanobacteria Species 0.000 description 4
- 201000004624 Dermatitis Diseases 0.000 description 4
- 231100000111 LD50 Toxicity 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 239000002537 cosmetic Substances 0.000 description 4
- 229940008099 dimethicone Drugs 0.000 description 4
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 206010067484 Adverse reaction Diseases 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- 206010040914 Skin reaction Diseases 0.000 description 3
- 230000006838 adverse reaction Effects 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 150000003278 haem Chemical class 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000003020 moisturizing effect Effects 0.000 description 3
- 230000035483 skin reaction Effects 0.000 description 3
- 231100000430 skin reaction Toxicity 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- 241001071795 Gentiana Species 0.000 description 2
- 241001135871 Gentiana scabra Species 0.000 description 2
- 238000011887 Necropsy Methods 0.000 description 2
- 206010067482 No adverse event Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000037336 dry skin Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000000744 eyelid Anatomy 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000003305 oral gavage Methods 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000036558 skin tension Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000009182 swimming Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000036572 transepidermal water loss Effects 0.000 description 2
- 206010000188 Abnormal weight gain Diseases 0.000 description 1
- 206010060933 Adverse event Diseases 0.000 description 1
- 102000010637 Aquaporins Human genes 0.000 description 1
- 108010063290 Aquaporins Proteins 0.000 description 1
- 102000014654 Aromatase Human genes 0.000 description 1
- 108010078554 Aromatase Proteins 0.000 description 1
- 229940122815 Aromatase inhibitor Drugs 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 208000014085 Chronic respiratory disease Diseases 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 206010051559 Corneal defect Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 208000035874 Excoriation Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 102000004125 Interleukin-1alpha Human genes 0.000 description 1
- 108010082786 Interleukin-1alpha Proteins 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Natural products O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 1
- 206010058667 Oral toxicity Diseases 0.000 description 1
- 241000283977 Oryctolagus Species 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 208000006787 Port-Wine Stain Diseases 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 206010040830 Skin discomfort Diseases 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 206010040954 Skin wrinkling Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 241000270666 Testudines Species 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 231100000460 acute oral toxicity Toxicity 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000015294 blood coagulation disease Diseases 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 239000008358 core component Substances 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- NJDNXYGOVLYJHP-UHFFFAOYSA-L disodium;2-(3-oxido-6-oxoxanthen-9-yl)benzoate Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=CC(=O)C=C2OC2=CC([O-])=CC=C21 NJDNXYGOVLYJHP-UHFFFAOYSA-L 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 231100000040 eye damage Toxicity 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000000774 hypoallergenic effect Effects 0.000 description 1
- 230000000642 iatrogenic effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000005732 intercellular adhesion Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 231100000286 mucous membrane, eye irritation or corrosion testing Toxicity 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 231100000418 oral toxicity Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 238000009602 toxicology test Methods 0.000 description 1
Images
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Cosmetics (AREA)
Abstract
The invention discloses blue algae cream with a soothing and repairing effect and a preparation method thereof, wherein the blue algae cream is suitable for children and comprises the following steps: 5-15% of humectant, 5-10% of emollient, 1-4% of emulsifier, 0.5-1% of thickener, 0.3-0.8% of antioxidant, 0.03-0.06% of chelating agent, 0.01-0.03% of aromatic and 2-10% of skin conditioner; the skin conditioner comprises radix Gentianae extract 1-5%, blue algae 0.3-2%, yeast/rice fermentation filtrate 0.5-2%, vitamin B12.1-1.0%, milfoil extract 0.01-0.1%, and pure water 65-85%. According to the invention, the soothing and repairing agent has a very remarkable effect on sensitive skin after being used, is safe, mild and non-irritating, and is particularly suitable for children.
Description
Technical Field
The invention relates to the technical field of skin care products, in particular to blue algae cream with a soothing and repairing effect and suitable for children and a preparation method thereof.
Background
Children's skin differs from adults in morphology, physiology, function, etc. although the basic structure is not much different from adults: (1) Thinner skin, less hair, weaker intercellular adhesion, and less sweat gland secretion; (2) the absorption of the external medicine is more coated on the same part; (3) strong sensitivity to external stimuli; (4) increased susceptibility to bacterial infection; (5) reduced reactivity to contact allergens, and the like. For the reasons, the skin of the children is more sensitive, and the skin sensitive symptoms such as dryness, desquamation, redness, pruritus, eczema and the like appear.
The gentian extract has a good activating effect on luciferase as a skin conditioner, shows that the gentian extract has an effect on atopic dermatitis and allergy of the skin, can inhibit stimulation and has an anti-inflammatory effect; at the same time, the activation of aromatase shows that the aromatase inhibitor has the function of regulating the local estrogen level of the skin and has the functions of inhibiting and resisting elastase.
The traditional process of glycerol Glucoside (glycocide) is a glycoside compound formed by connecting glycerol and glucose molecules through a glycosidic bond. The glycerol glucoside can promote the synthesis of aquaporins, maintain osmotic balance, bring required moisture to skin cells, prevent inflammation, and also has obvious effects on improving skin elasticity, reducing skin redness, repairing barriers and reducing crow's feet. More importantly, however, the inventors found that the glycerol glucoside and derivative products prepared by the biological production technology from the blue algae derived from algae, wherein the di-alpha-glycerol glucoside can obviously inhibit the degranulation reaction of mast cells, obviously reduce the release amount of the inflammatory factor IL-1 alpha, obviously reduce the release amount of the inflammatory factor IL-1 beta and other very obvious anti-inflammatory effects on the skin, thereby having particularly excellent skin-forming and soothing repairing effects, being safe and non-irritant, and being applicable to skin care products for soothing repairing, particularly the field of children skin care. However, the applications of this part have not been studied intensively yet.
Disclosure of Invention
Aiming at the defects in the prior art, the invention aims to provide the blue algae cream with the effect of relieving and repairing children and the preparation method thereof. To achieve the above objects and other advantages in accordance with the present invention, there is provided a blue algae cream having soothing and repairing effects suitable for children, comprising:
5-15% of humectant, 5-10% of emollient, 1-4% of emulsifier, 0.5-1% of thickener, 0.3-0.8% of antioxidant, 0.03-0.06% of chelating agent, 0.01-0.03% of aromatic and 2-10% of skin conditioner; the skin conditioner comprises 1-5% of radix Gentianae extract, 0.3-2% of blue algae, 0.5-2% of yeast/rice fermentation filtrate, 0.1-1.0% of vitamin B12, 0.01-0.1% of milfoil extract, and 65-85% of pure water.
Preferably, the skin care product comprises 8-10% of a moisturizing agent, 6-8% of an emollient, 2-3% of an emulsifier, 0.6-0.8% of a thickening agent, 0.4-0.6% of an antioxidant, 0.04-0.06% of a chelating agent, 0.01-0.02% of a fragrance and 3-8% of a skin conditioner; the skin conditioner comprises 2-4% of radix Gentianae extract, 0.3-1.0% of blue algae, 0.8-1.5% of yeast/rice fermentation filtrate, 0.1-0.6% of vitamin B, 0.01-0.08% of yarrow extract and 70-80% of pure water.
The most preferred scheme is as follows: 9.31% of humectant, 7.5% of emollient, 2.0% of emulsifier, 0.75% of thickener, 0.5% of antioxidant, 0.05% of chelating agent, 0.01% of aromatic and skin conditioner;
the skin conditioner comprises radix Gentianae extract 3%, blue algae 0.5%, yeast/rice fermentation filtrate 1.0%, vitamin B120.2%, milfoil extract 0.01%, and water in balance.
Preferably, the humectant is glycerin, butylene glycol, 1,2-pentanediol, 1,2-hexanediol, or erythritol.
Preferably, the emollient is dimethicone or dimethiconol.
Preferably, the emulsifier is a C14-22 alcohol or a C12-20 alkyl glucoside.
Preferably, the chelating agent is disodium EDTA.
Preferably, the thickener is polyacrylate crosspolymer-6 or carbomer.
Preferably, the aromatic is bergamot fruit oil and the cyanobacteria is di-alpha-glyceroglucoside.
A preparation method of blue algae cream with the effect of relieving and repairing children comprises the following steps:
s1, accurately weighing each component material in the formula components, and cleaning production equipment;
s2, preparing an oil phase: adding emollient and emulsifier into oil phase pan, stirring at 15-25 rpm, heating to 80-82 deg.C, and dissolving completely to obtain liquid;
s3, preparing a water phase: injecting accurately weighed pure water into a clean and disinfected vacuum emulsifying pot, adding a chelating agent, starting heating and high-speed homogenizing, slowly spraying a thickening agent and an emulsifying agent in sequence, homogenizing for 10-15min until no fine particles are dissolved completely, stopping homogenizing, adding a humectant, starting external stirring for 15-25 r/min, starting internal stirring for 25-40 r/min, heating to 82-85 ℃, starting vacuumizing, starting high-speed homogenizing in a vacuum state, filtering the material in the step S2 by a 400-mesh filter screen, pumping into a vacuum emulsifying cylinder, homogenizing for 5min, adding the rest of emollient and emulsifying agent, homogenizing for 5-8min at high speed, starting external stirring for 10-25 r/min, stirring for 20-35 r/min, preserving heat and defoaming for 20min, and starting cooling after observing that no bubbles exist in a material body;
s4, when the temperature is reduced to 60 ℃, adding arginine into a clean container, mixing, stirring, dissolving and adding into a production cylinder after the arginine is transparent, opening the container to stir for 10-25 r/m, stirring for 20-35 r/m, and stirring for 5min;
s5, when the temperature is reduced to 45 ℃, adding an antioxidant into a clean container, stirring until the antioxidant is dissolved and transparent (the antioxidant can be properly heated to 50 ℃ and can not exceed the temperature), then adding the antioxidant into a production cylinder, sequentially adding the rest components, starting external stirring for 10-25 r/min, starting internal stirring for 20-35 r/min, and stirring for 5min;
s6, adding the vitamin B12 disinfected by ozone into a clean container, stirring until the vitamin B12 is dissolved uniformly, adding the mixture into a production cylinder, and stirring for 10-15min;
and S7, sampling and detecting, and filtering and discharging the qualified product by using a 200-mesh filter screen.
Compared with the prior art, the invention has the beneficial effects that: according to the blue algae cream suitable for children, the blue algae core component of the di-alpha glycerol glucoside is added, the yeast/rice fermentation filtrate of the GENTIANA SCABRA (GENTIANA SCABRA) extract, the vitamin B12 and the yarrow (ACHILLEA MILLEFOLIUM) extract are cooperated, the compatibility is good, the effect of good relieving and repairing is achieved, the skin is moist and comfortable after the blue algae cream is used, the safety is high, the blue algae cream is mild and non-irritating, and the blue algae cream is particularly suitable for children.
Drawings
FIG. 1 is a graph showing the change of water content of stratum corneum of skin at different time on a test site according to the cyanobacteria cream with soothing and repairing effects for children and the preparation method of the cyanobacteria cream;
FIG. 2 is a graph showing the change of the skin moisture loss measurement values of the skin at different time points of the test site according to the blue algae cream with soothing and repairing effects for children and the preparation method of the blue algae cream;
FIG. 3 is a graph showing the change of hemoglobin concentration at different time points on the skin of a test part of the cyanobacteria cream with soothing and repairing effects and the preparation method thereof suitable for children according to the present invention;
FIG. 4 is a graph showing the change of the red area ratio of the skin at different time points according to the blue algae cream with soothing and repairing effects for children and the preparation method of the blue algae cream;
FIG. 5 is a graph of the change of skin at different time points a of a blue algae cream with soothing and repairing effects for children and a preparation method thereof according to the invention;
FIG. 6 is a typical image of testers tera3Dcs of the blue algae cream with soothing and repairing effects for children and the preparation method according to the present invention.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the drawings in the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Example 1
A blue algae cream with soothing and repairing effects suitable for children comprises: humectant 8.52%, emollient 6.85%, emulsifier 1.8%, thickener 0.65%, antioxidant 0.45%, chelating agent 0.05%, fragrance 0.02% and skin conditioner 8%; the skin conditioner comprises 2% of radix Gentianae extract, 0.8% of blue algae, 1.2% of yeast/rice fermentation filtrate, 0.2% of vitamin B, 0.02% of milfoil extract and the balance of water.
Further, the humectant is glycerin, butylene glycol, 1,2-pentanediol, 1,2-hexanediol or bryol.
Further, the emollient is dimethicone or dimethiconol.
Further, the emulsifier is a C14-22 alcohol or a C12-20 alkyl glucoside.
Further, the chelating agent is disodium EDTA.
Further, the thickening agent is polyacrylate cross-linked polymer-6 or carbomer.
Further, the aromatic is bergamot fruit oil, and the blue algae is di-alpha-glycerol glucoside.
Example 2
A blue algae cream with soothing and repairing effects suitable for children comprises: 9.2% of humectant, 7.0% of emollient, 2.2% of emulsifier, 0.6% of thickener, 0.6% of antioxidant, 0.04% of chelating agent, 0.01% of aromatic and 7% of skin conditioner; the skin conditioner comprises radix Gentianae extract 1.5%, blue algae 0.6%, yeast/rice fermentation filtrate 1.5%, vitamin B12.4%, milfoil extract 0.01%, and water in balance.
Further, the humectant is glycerin, butylene glycol, 1,2-pentanediol, 1,2-hexanediol or bryol.
Further, the emollient is dimethicone or dimethiconol.
Further, the emulsifier is C14-22 alcohol or C12-20 alkyl glucoside.
Further, the chelating agent is disodium EDTA.
Further, the thickening agent is polyacrylate cross-linked polymer-6 or carbomer.
Further, the aromatic is bergamot fruit oil, and the blue algae is di-alpha-glycerol glucoside.
Example 3
A blue algae cream with soothing and repairing effects suitable for children comprises: 9.31% of humectant, 7.5% of emollient, 2.0% of emulsifier, 0.75% of thickener, 0.5% of antioxidant, 0.05% of chelating agent, 0.01% of aromatic and skin conditioner;
the skin conditioner comprises radix Gentianae extract 3%, blue algae 0.5%, yeast/rice fermentation filtrate 1.0%, and vitamin B 12 0.2% of yarrow extract, 0.01% of yarrow extract and the balance of water.
Further, the humectant is glycerin, butylene glycol, 1,2-pentanediol, 1,2-hexanediol or bryol.
Further, the emollient is dimethicone or dimethiconol.
Further, the emulsifier is a C14-22 alcohol or a C12-20 alkyl glucoside.
Further, the chelating agent is disodium EDTA.
Further, the thickening agent is polyacrylate cross-linked polymer-6 or carbomer.
Further, the aromatic is bergamot fruit oil, and the blue algae is di-alpha-glycerol glucoside.
A preparation method of blue algae cream with a soothing and repairing effect suitable for children comprises the following steps:
s1, accurately weighing each component material in the formula components, and simultaneously cleaning production equipment;
s2, preparing an oil phase: adding emollient and emulsifier into oil phase pan, stirring at 15-25 rpm, heating to 80-82 deg.C, and dissolving completely to obtain liquid;
s3, preparing a water phase: injecting accurately weighed pure water into a clean and disinfected vacuum emulsifying pot, adding a chelating agent, starting heating and high-speed homogenizing, slowly spraying a thickening agent and an emulsifying agent in sequence, homogenizing for 10-15min until no fine particles are dissolved completely, stopping homogenizing, adding a humectant, starting external stirring for 15-25 r/min, starting internal stirring for 25-40 r/min, heating to 82-85 ℃, starting vacuumizing, starting high-speed homogenizing in a vacuum state, filtering the material in the step S2 by a 400-mesh filter screen, pumping into a vacuum emulsifying cylinder, homogenizing for 5min, adding the rest of emollient and emulsifying agent, homogenizing for 5-8min at high speed, starting external stirring for 10-25 r/min, stirring for 20-35 r/min, preserving heat and defoaming for 20min, and starting cooling after observing that no bubbles exist in a material body;
s4, when the temperature is reduced to 60 ℃, adding arginine into a clean container, mixing, stirring, dissolving and adding into a production cylinder after the arginine is transparent, opening the container to stir for 10-25 r/m, stirring for 20-35 r/m, and stirring for 5min;
s5, when the temperature is reduced to 45 ℃, adding an antioxidant into a clean container, stirring until the antioxidant is dissolved and transparent (the antioxidant can be properly heated to 50 ℃ and can not exceed the temperature), then adding the antioxidant into a production cylinder, sequentially adding the rest components, starting external stirring for 10-25 r/min, starting internal stirring for 20-35 r/min, and stirring for 5min;
s6, adding the vitamin B12 sterilized by ozone into a clean container, stirring until the vitamin B12 is dissolved uniformly, adding the mixture into a production cylinder, and stirring for 10-15min;
and S7, sampling and detecting, and filtering and discharging the qualified product by using a 200-mesh filter screen.
Taking the example 3 as a test sample, a comprehensive safety and efficacy test is carried out on the efficacy of the blue algae cream with the soothing and repairing efficacy for children on the soothing and repairing efficacy.
1. Acute eye irritation test
1. Experimental animals and breeding environment:
animal information: japanese white rabbit, normal grade
Animal number: 3 females, 2.26-2.36 kg
Breeding unit: beijing City Changyang Xishan farm (laboratory animal production license number: SCXK (Jing) 2021-0008)
Animal quality certification number: 110329220100037873
License number for experimental animals: SYXK 2018-0002
A breeding environment: the temperature is 20.9-23.0 ℃, and the average daily temperature difference is less than or equal to 1.8 ℃; the relative humidity is 46.7 to 65.3 percent
The types of the feed are as follows: rabbit maintenance feed
The feed source is as follows: si Bei Fu (Beijing) Biotechnology Inc. (SCXK (Beijing) 2019-0010)
Feed quality certification number: 1103242200081598
2. The test method comprises the following steps:
both eyes of the test animals were examined 24h before the start of the test. Animals with symptoms of eye irritation, corneal defects, and conjunctival damage were not used for the test. The animal was tipped right, the left eye was allowed to stand obliquely upward, the left lower eyelid was gently pulled open, and 0.1mL of the test article was placed directly into the conjunctival sac. The eyelids were closed 1s after exposure and no rinse was applied for 24h after test substance administration. The right eye was not treated for self-control. The conjunctival, corneal and iris lesions were examined and recorded at 1h, 24h, 48h, 72h, 4d, and 7d after administration. The scoring was performed according to the eye damage scoring criteria table in the technical Specification for cosmetic safety (2015 edition). Eyes of all animals were further examined 24h later using sodium fluorescein. If no stimulus response appears in 72 hours, the test is terminated, otherwise, the observation time needs to be prolonged and is not more than 21 days. And after the test is finished, grading the eye irritation response intensity according to a product eye irritation response grading table according to the highest integral mean value and the recovery time of the irritation response of the cornea, the iris and the conjunctiva of the animal at observation points of 24h, 48h and 72h respectively.
And (3) test results:
test result of acute eye irritation of test object to rabbit
(No flushing)
Note: the integrated mean retains 2 decimal places.
4. And (4) test conclusion:
acute eye irritation of the test article to rabbits: under (no-rinse) conditions, it is non-irritating.
Toxicology test item (acute oral toxicity test)
1. Experimental animals and feeding environment:
animal information: ICR mice, SPF grade
Number of animals: 5 males, 19-20 g; 5 females, 19-21 g.
Breeding unit: si Bei Fu (Beijing) Biotechnology Inc. (SCXK (Beijing) 2019-0010)
Animal quality certification number: 110324220103370234
License number for experimental animals: SYXK (jin) 2018-0002
A breeding environment: the temperature is 20.9-23.4 ℃, and the average daily temperature difference is less than or equal to 1.8 ℃; the relative humidity is 40.0 to 69.7 percent
The types of the feed are as follows: 60Co radiation sterilization rat complete pellet feed
The feed source is as follows: si Bei Fu (Beijing) Biotechnology Co., ltd. (SCXK (Beijing) 2019-0010)
Feed quality certification number: 1103222200086240
The test method comprises the following steps:
sample preparation: the tested sample is prepared into the required concentration (250 mg/mL) by pure water, and the test sample is prepared as it is. The test sample is placed at normal temperature in the sample feeding process, and the sample feeding process does not exceed half a day.
And (3) experimental design: by using the limit test method, 10 ICR mice, each half of the mice, are set in the group with 5000mg/kg dose. Animals were given test samples by oral gavage after overnight fasting for 4 hours and mice were observed for toxicity performance 14 days after sample administration. At the end of the test, the surviving animals were euthanized and gross dissected to visualize pathological changes in their tissues and organs.
Sample administration route and method: a syringe with a gavage needle is adopted for oral gavage sample feeding (0.2 mL/10 g), and the sample feeding time is morning.
And (3) clinical observation: the observation was performed 1 time per day for 14 days.
And (3) measuring the body weight: the observation period was measured 1 time per week.
And (3) pathological examination: all test animals were subjected to gross necropsy.
And (4) judging a result: based on the median lethal dose (LD 50) of the test samples, the toxicity of the samples was graded according to the test of the following table.
3. And (3) test results:
clinical signs: after the administration, no abnormal signs associated with the administration were observed, and neither the male nor the female animals died during the observation period (see table 1 for details).
TABLE 1 summary of animal deaths
Weight change: the animals in each group had no abnormal weight gain before infection, on day 7 and 14 (see table 2 for details).
Table 2. Animal body weights (g,
)
gross pathology examination results: at the end of the observation period, 14 days, no significant abnormalities were seen in the surviving animals by gross necropsy (see table 3 for details).
TABLE 3 gross animal dissection
4. And (4) test conclusion:
the test result shows that under the test condition, the test sample of the turtle father blue algae soothing and repairing cream is administrated by gastric lavage with the dosage of 5000mg/kg, the female rat and the male rat do not die, and abnormal physical sign expression is not seen. The test sample has acute oral median lethal dose (LD 50) of more than 5000mg/kg body weight for both female and male ICR mice. Oral toxicity is classified as practically non-toxic.
3. Patch test on human skin
1. Subject: the total of 30, 3 men and 27 women, the age of 23-58 years, the average age of 42.37 +/-10.20 years, meet the volunteer enrollment criteria of the subjects.
2. The spot test method comprises the following steps: a spot test device of a table grid is selected, a closed spot test method is adopted, about 0.020g-0.025g (solid) 0.020mL-0.025mL (liquid) of a tested object is placed in a spot test device, an external hypoallergenic adhesive tape is pasted on the back of a tested object, the tested object is removed after 24 hours, skin reactions are observed after 0.5 hour, 24 hours and 48 hours after removal respectively, and the result is recorded according to the skin reaction grading standard in the current effective technical specification.
3. Results of the experiment
Summary of cosmetic human skin Patch test results
See figure 1.
4. The test of the effect of relieving and repairing:
1. the test method comprises the following steps:
control protocol: self-comparison.
Testing time points: before use of the sample (D) 0 ) Day 14 of use of the sample (D) 14 ) Day 28 of sample use (D) 28 )。
Sample size: subject 35 was included in the combo.
Testing parts: a face.
And (3) testing environment: temperature (20-22 deg.C), relative humidity (40-60%).
Evaluation indexes are as follows:
2. test apparatus and material
The device comprises a CK Corneometer CM825 skin stratum corneum water content tester, a CK TM300 skin percutaneous water loss tester, a CK MX18 melanin heme tester, an Antera3Dcs multifunctional 3D skin imaging measuring instrument, a clinical evaluation mirror, a pipette, lactic acid, normal saline, mild facial cleanser, 75% ethanol, a cotton swab, a non-scrap water absorption dry paper towel and the like.
3. Volunteers require:
(1) Volunteer enrollment criteria
a. The health condition is good when the patient is 18-50 years old;
b. self-evaluation is sensitive skin, and the lactic acid stimulation test is positive (more than or equal to 3 points);
c. and willing to sign informed consent, and having time to cooperate to complete the whole test.
(2) Volunteer exclusion criteria
a. The part to be tested is applied with any external medicine within nearly two months;
b. those who use antihistamines for nearly one week or immunosuppressants for nearly one month;
c. patients with inflammatory dermatoses (acne rosacea, seborrheic dermatitis, hormone-dependent dermatitis, contact dermatitis, atopic dermatitis, and lupus erythematosus) are not cured clinically;
d. insulin-dependent diabetic patients;
e. patients suffering from asthma or other chronic respiratory diseases undergoing therapy;
f. those who receive anti-cancer chemotherapy in approximately six months;
g. patients with immunodeficiency or autoimmune disease;
h. pregnant or lactating women;
i. obvious scars, pigments, atrophy, port wine stains, sunburn, wounds, abrasion, tattoos or other flaws exist at the skin test part or the accessory, and the judgment of the test result is influenced;
j. similar facial trials, oral drug trials or other clinical trials have been enrolled in approximately two months;
k. facial cosmetic surgery, and other cosmetic modalities that may affect the sensitive state of the skin, have been performed in approximately three months;
l, those with high constitutional sensitivity;
m, known to be allergic to cosmetic or daily chemical ingredients, alcohol, rubber, nonwoven fabric, drugs, or the like;
n, those who need to be exposed to outdoor sunlight for a long time due to work or other reasons;
o, other iatrogenic problems may affect the outcome of the test (e.g., a history of blood coagulation disorders, severe hyperglycemia, hypertension, hyperlipidemia, mental illness, or other major illness);
p, other clinical assessments considered unsuitable for participants;
q, non-volunteer participants or those who cannot complete the prescribed trial content as required.
4. The test flow comprises the following steps:
cleaning the face of a qualified testee meeting the group entry condition by using mild facial cleanser, and sucking water from a non-dandruff facial tissue; sitting still for 30 minutes in the test environment; visual assessment of the subject's facial skin by the investigator; the subject fills out a self-assessment questionnaire; instrument tests (Antera 3DGs image acquisition, skin moisture content determination, transdermal moisture loss determination) were then performed. After all tests are finished, the product is distributed to the subjects and the using method of the product is guided, the subjects use the product at home according to the using instructions, visit is carried out on the 14 th day and the 28 th day, and the relevant index tests are finished according to the above process.
5. The product using method comprises the following steps:
after cleaning, a proper amount of the product is gently applied to the whole face, 2 times a day, once in the morning and evening, and continuously used for 28 days.
Safety and adverse reaction treatment:
subjects signed an informed consent. Any discomfort occurs in the process of using the product, and the product is returned to the detection center in time for the doctor to make an assessment; subjects were asked at each visit for adverse reactions, all of which were faithfully recorded.
6. The statistical method comprises the following steps:
data analysis was performed using SPSS25 statistical software. For instrumental quantitative data, expressed as mean ± standard deviation; if the data obeys normal distribution, different time points and D 0 The comparison of (1) adopts paired t test; if the data is the skewed data, nonparametric inspection is adopted. Grading score data for investigator evaluation and subject self-evaluation, different time points and D 0 The comparison of (A) and (B) adopts a Wilcoxon test; the subject post-use experience and effect questionnaire was statistically distributed in two categories. Statistically significant differences were noted for data, P < 0.05 marked with an x in the graph and P < 0.01 marked with an x in the graph.
7. The experimental results are as follows:
(1) Description of the Condition of a subject
(1) The number of people entering the group and the completion condition
TABLE 1 number of test subjects and completion
(2) Age (age)
TABLE 2 age distribution of subjects
Note: subject information is detailed in figure 2.
(3) Typing of sensitive skin
TABLE 3 Subjects' susceptibility skin typing
(2) Security assessment
(1) Safety assessment of test samples by investigators
A total of 35 asian adult healthy female subjects between 20 and 50 years of age were enrolled in this study and evaluated for their potential to cause a skin discomfort reaction using test samples for 28 consecutive days under normal conditions. Wherein 1 subject can not complete follow-up visit according to requirements due to personal reasons, 1 subject quits the test due to skin allergy caused by swimming and 33 subjects complete the test according to requirements. The resulting Gao demonstrated that 33 subjects did not experience any adverse reactions associated with the samples during 28 days of continuous use of the test samples.
(2) Subject self assessment
The test samples were used continuously for 28 days by the subjects without any discomfort, and all subjects considered the product to be mild and non-irritating.
TABLE 4 test procedure adverse event incidence
Lactic acid sting test results:
TABLE 5 lactic acid sting test Scoring before and after product use
The lactic acid sting test is a semi-subjective assessment method widely used for sensitive skin judgment. At room temperature, a 10% lactic acid solution was applied to the nasolabial fold and any one cheek and scored according to the subjective symptoms of the subject at 0, 2.5 and 5min, respectively, on a 4 point scale (0 for no sensation, 1 for mild stinging, 2 for moderate stinging, and 3 for severe stinging). The fractions of the two times are added, and the lactic acid stabbing pain reaction is positive if the total fraction is more than or equal to 3.
The statistical result shows that the lactic acid sting reaction score after the product is used for 28 days is obviously reduced compared with the basic value before the product is used, and the difference has statistical significance (P is less than 0.01).
(3) Results of instrumental testing
(1) Water content of horny layer
TABLE 6 stratum corneum water content at different time points of the skin at the test sites
Note: 1.D 0 Before use of the sample: d 14 Indicating day 14 using the sample: d 28 Indicating day 28 of use of the sample. (same below) 2.P values respectively represent D 14 、D 28 Measured value and D 0 Statistical analysis of the measurements significance results: p < 0.05 label, P < 0.01 label. (the same below)
Stratum corneum moisture content was measured using a Corneometer CM825, and a higher measurement indicated a higher moisture content of the stratum corneum at the site of the test. The statistical results show that: skin at test site D 14 、D 28 Water content of horny layer and D 0 The difference is statistically significant (P is less than 0.05).
(2) Transepidermal water loss
TABLE 7 measurement of epidermal water loss at different time points of the skin at the test sites
Skin indirectly reflects the function of epidermal permeability barrier through epidermal water loss, and the value of sensitive skin is often increased. The research adopts TM300 to carry out testing, and the lower the measured value is, the less the water loss of the skin at the tested part through the epidermis is, and the better the function of the indirect reaction epidermal permeability barrier is. The statistical results show that: skin at test site D 14 、D 28 There was a trend of decline in the transepidermal water loss measurements but no statistical difference (P > 0.05).
(3) Heme (MX 18)
TABLE 8 hemoglobin content of skin at different time points of the test sites
The hemoglobin content of the skin at the test site was measured by MX18, and a higher measurement indicates a higher hemoglobin content in the skin at the test site, and a redder skin. The statistical results show that: test site skin of subjectAt D 28 The heme content and D of 0 The difference is remarkably reduced, and the difference has statistical significance (P is less than 0.01).
(4) Red zone area ratio (Antera 3 Dcs)
TABLE 9 area ratio (%) -of red zone at different time points of skin at test sites
After the skin of the test part is imaged by using Antera3Dcs, the red area ratio is obtained by software analysis and calculation. The higher the measurement, the higher the proportion of the red area of the skin at the test site. The statistical results show that: skin at test site D 14 、D 28 Red region area ratio of (A) to (D) 0 The comparison had a decreasing trend but no statistical difference (P > 0.05).
(5) Skin a value (Antera 3 Dcs)
TABLE 10 values a at different time points of the skin at the test sites
Facial images were collected using Antera3Dcs and analyzed by software to derive test site skin a values. The a value represents the degree of redness, with a larger value indicating that the skin is more red. The statistical results show that: skin at test site D 14 、D 28 A and D 0 The comparison shows no obvious change (P is more than 0.05).
(4) Subjective evaluation section
(1) Subjective visual assessment of the skin condition of the face of a subject by a researcher
Before using the product, on days 14 and 28, the researchers carried out subjective visual scoring of the condition of the facial skin of the subjects, with higher scores indicating more severe.
TABLE 11 visual assessment score of investigator's skin condition of subject before and after product use
Statistical results show that researchers scored the facial skin erythema, redness, dryness, scaling of subjects at D 14 、D 28 And D 0 The difference is remarkably reduced, and the difference has statistical significance (P is less than 0.05).
(2) Subject self assessment
The subjects 'experience and effect evaluation questionnaire options after using the product were evaluated using a 5-point method, i.e., very agreeing/very agreeing, agreeing/satisfying, general, disagreeing/unsatisfying, and very disagreeing/very dissatisfying, with different scores, respectively, "very agreeing/very agreeing" with score 5, "agreeing/satisfying" with score 4, "general" with score 3, "disagreeing/dissatisfying" with score 2, "very disagreeing/very dissatisfying" with score 1, and subjects's score 4 or more were considered as agreeing with the test problem. And (4) performing two-term distribution test statistics, taking 0.50 as a test proportion, and if P is less than 0.05, determining that the acceptance rate of the test problem is more than 50%. The results are detailed in Table 12.
TABLE 12 subjective feeling and Effect evaluation of subjects after product application
Note: d 1 Shows the evaluation of the feeling of use after the first use: d 14 Represents evaluation of feeling of use 14 days after use; d 28 The evaluation of the feeling of use after 28 days of use is shown.
Through two distribution tests, the acceptance rate of the test questions in the questionnaire by the test subjects exceeds 50 percent. Wherein 100% of the subjects considered the product to be mild and non-irritating to the skin and improved in the dry skin condition at 14 days and 28 days of use of the test samples; the skin tension was considered to be improved in 100% and 96.97% of the subjects, respectively; 93.94% of the subjects, respectively, considered a relief from the skin redness; 100% of the subjects and 93.94% of the subjects respectively consider that the skin pruritus state is relieved and the skin prickling feeling is relieved; 96.97% and 100% of subjects, respectively, considered an improvement in the skin sensitivity state; 100% and 96.97% of the subjects considered the skin to be tender and smooth, and the skin tolerance was improved; 93.94%, 96.97% of the subjects considered the skin to be shinier, respectively; the total satisfaction rate of the product after 28 days of use is 100 percent.
8. Conclusion of the experiment
(1) In this test, the test site has a significantly increased stratum corneum water content and a significantly decreased hemoglobin content in the skin 28 days after application of the test sample, as compared to the pre-application baseline. This suggests that the test sample has a moisturizing effect on the skin at the test site under the study conditions.
(2) In this test, the skin hemoglobin content of the test site was significantly reduced 28 days after the test sample was applied to the subject, as compared to the baseline value prior to application; this suggests that under the study conditions, the test samples have soothing and repairing effects on the redness of the skin at the test site of the sensitive muscle subjects.
(3) In this test, the visual assessment score of the subject for objective signs of facial skin erythema, redness, dryness, scaling, etc. was significantly reduced by the investigator 28 days after use of the test sample as compared to before use. This suggests that the test sample improves the objective signs of the subject's sensitive skin under the study conditions.
(4) In this test, the subjective score for lactic sting in subjects was significantly reduced 28 days after use of the test sample compared to the pre-use baseline. At 14 days and 28 days after using the test samples, 100% of the subjects considered the product to be mild and non-irritating to the skin and improved in the dry skin condition; the skin tension was considered to be improved in 100% and 96.97% of the subjects, respectively; 93.94% of the subjects, respectively, considered a relief from the skin redness; 100% of the subjects and 96.97% of the subjects respectively consider that the skin pruritus state is relieved and the skin prickling feeling is relieved; 96.97% and 100% of subjects, respectively, considered an improvement in the skin sensitivity state; the skin tolerance was considered to be improved in 100%, 96.97% of the subjects, respectively. It is thus suggested that the test samples improve subjective discomfort to the subject's sensitive skin under the study conditions.
(5) In this test, 28 days after the test sample was used, no adverse reaction related to the test sample occurred and all subjects considered the product to be mild and non-irritating to the skin.
30 subjects had skin reactions at different observation times
Note: the results of the first 30 effective subjects were counted using a systematic sampling method.
The 14 th test subject did not follow up on time for personal reasons, and the 31 st test subject took the drug for skin allergy due to swimming, and the test was terminated.
In conclusion, 33 Asian adult healthy female sensitive skin subjects aged 20-50 years continuously use the test sample for 28 days under normal conditions, and the instrument measures the water content of the horny layer of the skin, the percutaneous water loss, the heme, the visual evaluation of researchers and the self evaluation of the subjects, so that the result shows that under the research condition, the test sample has the effects of moisturizing, soothing and repairing the skin at the test part of the sensitive skin subjects after being used for 28 days; no adverse reactions occurred in the 33 subjects using the test samples for 28 days.
The number of devices and the scale of the processes described herein are intended to simplify the description of the invention, and applications, modifications and variations of the invention will be apparent to those skilled in the art.
While embodiments of the invention have been described above, it is not limited to the applications set forth in the description and the embodiments, which are fully applicable in various fields of endeavor to which the invention pertains, and further modifications may readily be made by those skilled in the art, it being understood that the invention is not limited to the details shown and described herein without departing from the general concept defined by the appended claims and their equivalents.
Claims (9)
1. The blue algae cream with the effect of relieving and repairing children is characterized by comprising the following components in percentage by weight:
5-15% of humectant, 5-10% of emollient, 1-4% of emulsifier, 0.5-1% of thickener, 0.3-0.8% of antioxidant, 0.03-0.06% of chelating agent, 0.01-0.03% of aromatic and 2-10% of skin conditioner; the skin conditioner comprises radix Gentianae extract 1-5%, blue algae 0.3-2%, yeast/rice fermentation filtrate 0.5-2%, vitamin B12.1-1.0%, milfoil extract 0.01-0.1%, and pure water 65-85%.
2. The cyanobacterial cream with soothing and repairing effects suitable for children as claimed in claim 1, wherein the cyanobacterial cream comprises 8-10% of moisturizer, 6-8% of emollient, 2-3% of emulsifier, 0.6-0.8% of thickener, 0.4-0.6% of antioxidant, 0.04-0.06% of chelating agent, 0.01-0.02% of aromatic and 3-8% of skin conditioner; the skin conditioner comprises 2-4% of radix Gentianae extract, 0.3-1.0% of blue algae, 0.8-1.5% of yeast/rice fermentation filtrate, 0.1-0.6% of vitamin B, 0.01-0.08% of milfoil extract, and 70-80% of pure water.
3. The cyanobacterial cream with soothing and repairing effects suitable for children as claimed in claim 1, wherein the humectant is one or more of glycerin, butylene glycol, 1,2-pentanediol, 1,2-hexanediol or erythritol.
4. The cyanobacterial cream with soothing and repairing effects for children as claimed in claim 1, wherein the emollient is one or more of polydimethylsiloxane and dimethiconol.
5. The cyanobacterial cream with soothing and repairing effects suitable for children as claimed in claim 1, wherein the emulsifier is one or more of C14-22 alcohol and C12-20 alkyl glucoside.
6. The cyanobacterial cream with soothing and repairing effects suitable for children of claim 1, wherein the chelating agent is disodium EDTA.
7. The cyanobacterial cream with soothing and repairing effects suitable for children as claimed in claim 1, wherein the thickener is one or more of polyacrylate cross-linked polymer-6 or carbomer.
8. The cyanobacterial cream with soothing and repairing effects for children as claimed in claim 1, wherein the aromatic is bergamot fruit oil and the cyanobacterial is di-alpha-glyceroglucoside.
9. The method for preparing the cyanobacterial cream with the effect of relieving and repairing the children as claimed in claim 1, which comprises the following steps:
s1, accurately weighing each component material in the formula components, and cleaning production equipment;
s2, preparing an oil phase: adding emollient and emulsifier into oil phase pan, stirring at 15-25 rpm, heating to 80-82 deg.C, and dissolving completely to obtain liquid;
s3, preparing a water phase: injecting accurately weighed pure water into a clean and disinfected vacuum emulsifying pot, adding a chelating agent, starting heating and high-speed homogenizing, slowly spraying a thickening agent and an emulsifying agent in sequence, homogenizing for 10-15min until no fine particles are dissolved completely, stopping homogenizing, adding a humectant, starting external stirring for 15-25 r/min, starting internal stirring for 25-40 r/min, heating to 82-85 ℃, starting vacuumizing, starting high-speed homogenizing in a vacuum state, filtering the material in the step S2 by a 400-mesh filter screen, pumping into a vacuum emulsifying cylinder, homogenizing for 5min, adding the rest of emollient and emulsifying agent, homogenizing for 5-8min at high speed, starting external stirring for 10-25 r/min, stirring for 20-35 r/min, preserving heat and defoaming for 20min, and starting cooling after observing that no bubbles exist in a material body;
s4, when the temperature is reduced to 60 ℃, adding arginine into a clean container, mixing, stirring, dissolving and adding into a production cylinder after the arginine is transparent, opening the container to stir for 10-25 r/m, stirring for 20-35 r/m, and stirring for 5min;
s5, when the temperature is reduced to 45 ℃, adding an antioxidant into a clean container, stirring until the antioxidant is dissolved and transparent (the antioxidant can be properly heated to 50 ℃ and can not exceed the temperature), then adding the antioxidant into a production cylinder, sequentially adding the rest components, starting external stirring for 10-25 r/min, starting internal stirring for 20-35 r/min, and stirring for 5min;
s6, adding the vitamin B12 sterilized by ozone into a clean container, stirring until the vitamin B12 is dissolved uniformly, adding the mixture into a production cylinder, and stirring for 10-15min;
and S7, sampling and detecting, and filtering and discharging the qualified product by using a 200-mesh filter screen.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211011651.1A CN115969721A (en) | 2022-08-23 | 2022-08-23 | Blue algae cream with soothing and repairing effects and suitable for children and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211011651.1A CN115969721A (en) | 2022-08-23 | 2022-08-23 | Blue algae cream with soothing and repairing effects and suitable for children and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115969721A true CN115969721A (en) | 2023-04-18 |
Family
ID=85956915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211011651.1A Pending CN115969721A (en) | 2022-08-23 | 2022-08-23 | Blue algae cream with soothing and repairing effects and suitable for children and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115969721A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112315882A (en) * | 2020-11-23 | 2021-02-05 | 山东福瑞达生物工程有限公司 | Soothing, repairing and moisturizing cream and preparation method thereof |
| CN113244151A (en) * | 2021-05-31 | 2021-08-13 | 植然天成(北京)生物科技有限公司 | Soothing repair cream and preparation method thereof |
-
2022
- 2022-08-23 CN CN202211011651.1A patent/CN115969721A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112315882A (en) * | 2020-11-23 | 2021-02-05 | 山东福瑞达生物工程有限公司 | Soothing, repairing and moisturizing cream and preparation method thereof |
| CN113244151A (en) * | 2021-05-31 | 2021-08-13 | 植然天成(北京)生物科技有限公司 | Soothing repair cream and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 广州好肌肤科技有限公司: "海龟爸爸蓝藻舒缓修护霜", pages 3, Retrieved from the Internet <URL:《国产普通化妆品备案信息》> * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102406576B (en) | Prinsepia utilis Royle oil-containing functional skin care product and preparation method thereof | |
| EP3520796A1 (en) | Composition containing water-solubilized ursodeoxycholic acid for preventing or treating inflammatory skin disease or serious pruritus | |
| CN113456568A (en) | Composition for soothing, repairing and moisturizing skin and preparation method and application thereof | |
| US20150118334A1 (en) | Topical compositions for the treatment of chronic inflammatory skin disease | |
| US10933103B2 (en) | Dermatologic composition containing Escherichia coli and Enterococcus faecalis | |
| WO2012010022A1 (en) | New use of hesperetin | |
| CN115969721A (en) | Blue algae cream with soothing and repairing effects and suitable for children and preparation method thereof | |
| CN111888275B (en) | Composition and preparation method and application thereof | |
| CN117860624B (en) | Bionic sebum membrane composition with relieving effect and preparation method thereof | |
| CN116687778B (en) | Mild, tear-free and eye-penetrating and non-irritating amino acid facial cleansing foam for children and preparation method thereof | |
| CN110974716A (en) | Composition for preventing and treating striae gravidarum | |
| CN115607482A (en) | Soothing and moisturizing emulsion and preparation method thereof | |
| CN109091619A (en) | For the Chinese medicine external emulsifiable paste and preparation method thereof of skin health | |
| CN115054544B (en) | Anti-allergy and soothing foundation formula rich in yeast fermentation broth Supferm PO and preparation method thereof | |
| CN116327669B (en) | Acne-removing composition with skin barrier repairing function and preparation method thereof | |
| CN116869837B (en) | Anti-stinging and antiallergic composition and preparation method and application thereof | |
| CN107115383A (en) | With the skin care/therapeutic combination for preventing and treating dry skin syndrome effect | |
| Zhou | Clinical Application of Two Allergy-Relieving Formulas Replacing Topical Glucocorticosteroids in the Treatment of Cosmetic Dermatitis | |
| TWI491404B (en) | New use of hesperetin | |
| CN115969765A (en) | Composition with skin sensitivity relieving function and cosmetic thereof | |
| JP2003055191A (en) | Skin care treatment external preparation for atopic dermatitis and various xeroderma and rough skin diseases | |
| CN117243840A (en) | Fullerene repair moisturizing cream and preparation method and application thereof | |
| CN110384733A (en) | A kind of refined even gelling agent and preparation method thereof | |
| TWI421098B (en) | New use of new hesperidin | |
| Matysiak et al. | STUDIES ON THE FORMULATION AND FUNCTIONALITY OF AN INNOVATIVE LINE OF TOPICAL PRODUCTS FOR ATOPIC SKIN. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |